Biomanufacturing faces a deepening operational disconnect in its transition toward next-generation operations. Traditional standards once provided a reliable base, but the complexity of modern production is placing them under sustained pressure. The convergence of expanding therapeutic modalities, rising sustainability mandates and tightening capital conditions has exposed the functional constraints of these established foundations (1).

This tension is most evident as companies attempt to scale and modernize in parallel. The historical reliance on rigid, purpose-built infrastructure is at odds with a market that requires agility and rapid reconfiguration. To remain competitive, the industry is under pressure to significantly compress development timelines. This reality is driving a sector-wide realization that minor, incremental upgrades may no longer be sufficient. Instead, the focus is shifting toward addressing the fundamental constraints of facilities, processes, data and people as an integrated system.

The high cost of physical rigidity

Physical asset rigidity represents a core structural limitation of traditional manufacturing. In the past, the industry has relied on the construction of large-scale greenfield facilities, projects that typically require capital expenditure (CapEx) exceeding $100m and multi-year timelines for design, construction and validation (2).

This high-CapEx model requires organizations to make critical architectural and engineering decisions early in the project lifecycle. In many cases, these decisions are difficult and expensive to reverse once the facility is established. While such purpose-built environments are effective for single-product manufacturing, they present a significant strategic risk as pipelines become more diverse. For companies managing multiple modalities, these rigid assets risk becoming stranded. When a facility is hard-wired for a specific process, responding to changes in demand or technology requires a complex and time-consuming refit, creating a structural barrier that limits the ability to adopt emerging technologies or meet new regulatory requirements.

To counter this risk, operations must decouple the facility lifecycle from the product lifecycle. As detailed in the recent BioPhorum analysis, Pathway to Multi-Modal Manufacturing, moving away from dedicated lines toward a multi-modal footprint allows sites to pivot between different product classes within the same physical shell (3). This prevents the operational paralysis of stranded assets, ensuring that the manufacturing floor can adapt to pipeline changes without the prohibitive downtime of a full brownfield retrofit.

Digital pressures and the interoperability gap

Digital transformation promises increased speed and quality, but siloed data and disparate automation systems frequently obstruct progress. This lack of integration compounds physical infrastructure constraints, preventing the harmonization of production across sites and the advancement toward real-time release or autonomous control. The root of this digital stagnation is a long-standing reliance on manual oversight and empirical models that are insufficient for the complexity of modern bioprocessing and the high-volume data streams generated throughout the production lifecycle.

When data remains trapped in independent systems, real-time monitoring and optimization are severely restricted. Specifically, a lack of interoperable process analytical technology (PAT) forces organizations into off-line monitoring rather than gaining real-time insight into critical quality attributes (CQAs). Achieving digital maturity depends on aligning information technology (IT) and operational technology (OT) systems to enable integrated, data-driven workflows. Resolving this requires a move toward standardized equipment interfaces. Recent Facilities of the Future evaluations demonstrate that a “plug-and-play” approach – where equipment skids are vendor-agnostic and pre-validated – can drastically reduce the integration burden that currently consumes technical resources during changeovers (4).

The regulatory environment itself is modernizing, with the European Medicines Agency (EMA) Network Strategy to 2028 signaling the need for appropriate digital transformation to modernize its own processes (5). This implies that manufacturers must adopt higher levels of automation and optimization to remain compatible with a digital-first regulatory infrastructure, where real-time data integrity and automated reporting are the baseline.

The human element of digital transformation

The transition toward next-generation biomanufacturing is as much a human challenge as a technical one. Currently, the demand for specialized digital and scientific skills outpaces supply, slowing the adoption of new technologies and limiting operational resilience. According to the World Economic Forum (WEF) Future of Jobs Report 2025, across industries, 59 percent of the workforce will require reskilling or upskilling by 2030 (6) . This evolution is necessary to remain effective as automation and data-driven workflows become the industry standard.

Modernization requires shifting talent away from repetitive physical tasks toward high-value roles centered on complex decision-making and exception handling. Developing this human capacity is vital. Without a workforce capable of managing these systems, heavy technological investments will fail to provide the agility required by the modern market.

Sustainability and the evolving regulatory landscape

Environmental and regulatory expectations are also redefining operational success in biomanufacturing. Organizations face growing mandates to reduce waste and improve efficiency to achieve the industry's ambition to reduce environmental impact from manufacturing resource use. Once treated as a peripheral concern, environmental sustainability is now embedded in regulatory and policy expectations. The EMA Network Strategy to 2028 has integrated environmental sustainability into its core mission (5), aligning the pharmaceutical sector with the legal requirements of the European Green Deal and the Net-Zero Industry Act.

These mandates require a strategic modernization of manufacturing processes to actively reduce the sector's ecological footprint. In this tightening landscape, environmental accountability has become a critical component of a company's regulatory standing, making the transition to more sustainable, intensified processes a necessity for long-term compliance.

Why point solutions fail the system

The convergence of digital, workforce and sustainability pressures demonstrates that incremental change is no longer sufficient. When organizations address these interconnected challenges through isolated upgrades, such as adding a single digital tool or a specific piece of equipment, the result is often increased systemic complexity without a corresponding increase in agility.

These isolated improvements create high-maintenance technical debt. Because these systems are not designed for interoperability, each small upgrade requires custom integration that traps specialized staff in a cycle of troubleshooting and maintenance. This dynamic effectively slows the workflows these tools were intended to accelerate. Rather than streamlining the facility, these point solutions result in a fragmented technology landscape that lacks the standardization required for scalable deployment.

Furthermore, incremental improvements to reactive Quality by Testing (QbT) models cannot match the efficiency of a holistic Quality by Design (QbD) approach that integrates quality into the process itself (1). This lack of a systemic view leaves the inherent complexities of modern manufacturing unresolved and prevents the realization of meaningful gains in agility.

Scaling success through coordinated re-imagining

The industry has reached a breaking point where traditional biomanufacturing models can no longer sustain modern requirements. Legacy infrastructure, siloed data and the widening skills gap demonstrate that historical frameworks now constrain future growth. For manufacturing leaders, this shift requires a fundamental re-evaluation of how readiness is assessed, how investments are sequenced and how progress is coordinated across sites and functions.

Viewing facilities, processes, data and people as parts of a single operating system provides a more durable foundation for manufacturing resilience. This systemic perspective is becoming central to maintaining a license to operate under evolving environmental and digital expectations. Aligned in this way, the industry can move beyond perpetual catch-up and begin building operations capable of supporting higher levels of autonomy, speed and long-term resilience.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe